25-1085 New Policy Expands Access to Hepatitis C Treatment
Date: 10/27/25
Full-course dispensing now allowed as of October 1, 2025
Effective October 1, 2025, the California Department of Health Care Services (DHCS) has removed the 28-day supply limitation for Hepatitis C treatments under Medi-Cal RX. Physicians and other providers may now dispense up to a 12-week supply per fill -- supporting uninterrupted care and better health outcomes.
Why this matters
This policy change is backed by strong clinical evidence and strives to reduce barriers to care for Medi-Cal members.
- High completion rates among Medi-Cal members
- Glecaprevir/Pibrentasvir: 89% completion rate
- Sofosbuvir/Velpatasvir: 83% completion rate
Note: These are just some of the drugs affected by this policy change
- MINMON study confirms safety and effectiveness
- 89% of participants took 100% of their medication over 12 weeks
- 95% achieved sustained virologic response (SVR)
- Expanded dispensing supports justice-involved populations
- Enables treatment continuity for individuals transitioning from incarceration to the community
- Reduces risk of treatment interruption and need for complex regimens
What providers need to know
- Full-course dispensing is now permitted for eligible Hepatitis C treatments. Please visit Contract Drugs List
- This change aligns with DHCS efforts to improve access and outcomes for vulnerable populations
Questions?
For questions about dispensing changes or the applicable treatments, please contact Medi-Cal RX.
Additional information
Providers are encouraged to access the provider portal for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.
If you have questions regarding the information contained in this update, contact CalViva Health at
888-893-1569.
This information applies to Physicians and Participating Physician Groups (PPGs).
This information applies to Medi-Cal in Fresno, Kings and Madera counties.